{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:48:18Z","timestamp":1784958498302,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s13555-015-0078-1","type":"journal-article","created":{"date-parts":[[2015,6,25]],"date-time":"2015-06-25T07:38:22Z","timestamp":1435217902000},"page":"171-181","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea"],"prefix":"10.1007","volume":"5","author":[{"given":"Andrew William","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Marchese","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,26]]},"reference":[{"key":"78_CR1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaad.2013.07.001","volume":"69","author":"JJ Leyden","year":"2013","unstructured":"Leyden JJ. The evolving view of rosacea. J Am Acad Dermatol. 2013;69:S1.","journal-title":"J Am Acad Dermatol"},{"key":"78_CR2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1468-3083.2010.03751.x","volume":"25","author":"BE Elewski","year":"2011","unstructured":"Elewski BE, Draelos Z, Dreno B, et al. Rosacea\u2014global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol. 2011;25:188\u2013200.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"78_CR3","first-page":"277","volume":"92","author":"JQ Rosso Del","year":"2013","unstructured":"Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis. 2013;92:277\u201384.","journal-title":"Cutis"},{"key":"78_CR4","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mjd.2002.120625","volume":"46","author":"J Wilkin","year":"2002","unstructured":"Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46:584\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"78_CR5","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12385","volume":"169","author":"J Tan","year":"2013","unstructured":"Tan J, Blume-Peytavi U, Ortonne JP, et al. An observational cross-sectional survey of rosacea: clinical associations and progression between subtypes. Br J Dermatol. 2013;169:555\u201362.","journal-title":"Br J Dermatol"},{"key":"78_CR6","first-page":"694","volume":"11","author":"JQ Rosso Del","year":"2012","unstructured":"Del Rosso JQ, Gallo RL, Kircik L, et al. Why is rosacea considered to be an inflammatory disorder? The primary role, clinical relevance, and therapeutic correlations of abnormal innate immune response in rosacea-prone skin. J Drugs Dermatol. 2012;11:694\u2013700.","journal-title":"J Drugs Dermatol"},{"key":"78_CR7","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jaad.2013.04.045","volume":"69","author":"M Steinhoff","year":"2013","unstructured":"Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol. 2013;69:S15\u201326.","journal-title":"J Am Acad Dermatol"},{"key":"78_CR8","first-page":"1","volume":"91","author":"JQ Rosso Del","year":"2013","unstructured":"Del Rosso JQ, Gallo RL, Tanghetti E, Webster G, Thiboutot D. An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis. 2013;91:1\u20138.","journal-title":"Cutis"},{"key":"78_CR9","first-page":"16","volume":"5","author":"JQ Rosso Del","year":"2012","unstructured":"Del Rosso JQ. Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. J Clin Aesthet Dermatol. 2012;5:16\u201325.","journal-title":"J Clin Aesthet Dermatol"},{"key":"78_CR10","first-page":"26","volume":"5","author":"JQ Rosso Del","year":"2012","unstructured":"Del Rosso JQ. Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea. J Clin Aesthet Dermatol. 2012;5:26\u201336.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"Suppl 3","key":"78_CR11","doi-asserted-by":"crossref","first-page":"S211","DOI":"10.1016\/S0151-9638(11)70092-8","volume":"138","author":"A Parodi","year":"2011","unstructured":"Parodi A, Drago F, Paolino S, Cozzani E, Gallo R. Treatment of rosacea. Ann Dermatol Venereol. 2011;138(Suppl 3):S211\u20134.","journal-title":"Ann Dermatol Venereol"},{"key":"78_CR12","first-page":"623","volume":"20","author":"SR Feldman","year":"2014","unstructured":"Feldman SR, Huang WW, Huynh TT. Current drug therapies for rosacea: a chronic vascular and inflammatory skin disease. J Manag Care Spec Pharm. 2014;20:623\u20139.","journal-title":"J Manag Care Spec Pharm"},{"key":"78_CR13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00128071-200001030-00007","volume":"1","author":"KJ McClellan","year":"2000","unstructured":"McClellan KJ, Noble S. Topical metronidazole. A review of its use in rosacea. Am J Clin Dermatol. 2000;1:191\u20139.","journal-title":"Am J Clin Dermatol"},{"key":"78_CR14","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2133.1986.tb05764.x","volume":"115","author":"JP Leeming","year":"1986","unstructured":"Leeming JP, Holland KT, Bojar RA. The in vitro antimicrobial effect of azelaic acid. Br J Dermatol. 1986;115:551\u20136.","journal-title":"Br J Dermatol"},{"key":"78_CR15","first-page":"427","volume":"3","author":"AK Gupta","year":"2004","unstructured":"Gupta AK, Nicol K. The use of sulfur in dermatology. J Drugs Dermatol. 2004;3:427\u201331.","journal-title":"J Drugs Dermatol"},{"key":"78_CR16","first-page":"29","volume":"73","author":"JQ Rosso Del","year":"2004","unstructured":"Del Rosso JQ. Evaluating the role of topical therapies in the management of rosacea: focus on combination sodium sulfacetamide and sulfur formulations. Cutis. 2004;73:29\u201333.","journal-title":"Cutis"},{"key":"78_CR17","doi-asserted-by":"crossref","unstructured":"Abokwidir M, Fleischer AB. An emerging treatment: topical ivermectin for papulopustular rosacea. J Dermatolog Treat. 2015. doi: 10.3109\/09546634.2014.991672 .","DOI":"10.3109\/09546634.2014.991672"},{"key":"78_CR18","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.jaad.2013.06.009","volume":"69","author":"JQ Rosso Del","year":"2013","unstructured":"Del Rosso JQ. Management of facial erythema of rosacea: what is the role of topical alpha-adrenergic receptor agonist therapy? J Am Acad Dermatol. 2013;69:S44\u201356.","journal-title":"J Am Acad Dermatol"},{"key":"78_CR19","first-page":"650","volume":"12","author":"J Fowler Jr","year":"2013","unstructured":"Fowler J Jr, Jackson M, Moore A, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12:650\u20136.","journal-title":"J Drugs Dermatol"},{"key":"78_CR20","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/archderm.143.11.1369","volume":"143","author":"SD Shanler","year":"2007","unstructured":"Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol. 2007;143:1369\u201371.","journal-title":"Arch Dermatol"},{"key":"78_CR21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jdermsci.2014.04.002","volume":"75","author":"D Piwnica","year":"2014","unstructured":"Piwnica D, Rosignoli C, de Menonville ST, et al. Vasoconstriction and anti-inflammatory properties of the selective alpha-adrenergic receptor agonist brimonidine. J Dermatol Sci. 2014;75:49\u201354.","journal-title":"J Dermatol Sci"},{"key":"78_CR22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/bjd.12881","volume":"171","author":"K Benkali","year":"2014","unstructured":"Benkali K, Leoni M, Rony F, et al. Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea. Br J Dermatol. 2014;171:162\u20139.","journal-title":"Br J Dermatol"},{"key":"78_CR23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2133.2011.10716.x","volume":"166","author":"J Fowler","year":"2012","unstructured":"Fowler J, Jarratt M, Moore A, et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012;166:633\u201341.","journal-title":"Br J Dermatol"},{"key":"78_CR24","first-page":"56","volume":"13","author":"A Moore","year":"2014","unstructured":"Moore A, Kempers S, Murakawa G, et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol. 2014;13:56\u201361.","journal-title":"J Drugs Dermatol"},{"key":"78_CR25","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.jaad.2014.01.853","volume":"70","author":"D Ilkovitch","year":"2014","unstructured":"Ilkovitch D, Pomerantz RG. Brimonidine effective but may lead to significant rebound erythema. J Am Acad Dermatol. 2014;70:e109\u201310.","journal-title":"J Am Acad Dermatol"},{"key":"78_CR26","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.jaad.2013.10.054","volume":"70","author":"ET Routt","year":"2014","unstructured":"Routt ET, Levitt JO. Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%. J Am Acad Dermatol. 2014;70:e37\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"78_CR27","first-page":"33","volume":"14","author":"EA Tanghetti","year":"2015","unstructured":"Tanghetti EA, Jackson JM, Belasco KT, et al. Optimizing the use of topical brimonidine in rosacea management: panel recommendations. J Drugs Dermatol. 2015;14:33\u201340.","journal-title":"J Drugs Dermatol"},{"issue":"Suppl 1","key":"78_CR28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0039-6257(96)82030-3","volume":"41","author":"JB Serle","year":"1996","unstructured":"Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv Ophthalmol. 1996;41(Suppl 1):39\u201347.","journal-title":"Surv Ophthalmol"},{"key":"78_CR29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0002-9394(98)00286-4","volume":"127","author":"LJ Katz","year":"1999","unstructured":"Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol. 1999;127:20\u20136.","journal-title":"Am J Ophthalmol"},{"key":"78_CR30","first-page":"134","volume":"93","author":"JQ Rosso Del","year":"2014","unstructured":"Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis. 2014;93:134\u20138.","journal-title":"Cutis"},{"key":"78_CR31","first-page":"234","volume":"92","author":"JQ Rosso Del","year":"2013","unstructured":"Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis. 2013;92:234\u201340.","journal-title":"Cutis"},{"key":"78_CR32","unstructured":"Galderma Laboratories LP. Mirvaso (brimonidine) 0.33% topical gel product information. 2013. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204708lbl.pdf . Accessed 22 Apr 2014."},{"issue":"4","key":"78_CR33","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jaad.2014.05.073","volume":"71","author":"LA Swanson","year":"2014","unstructured":"Swanson LA, Warshaw EM. Allergic contact dermatitis to topical brimonidine tartrate gel 0.33% for treatment of rosacea. JAAD. 2014;71(4):832\u20133.","journal-title":"JAAD"},{"key":"78_CR34","unstructured":"Layton AM, Schaller M, Homey B, Hofmann M, Bewley A, Lehmann P, et al. Brimonidine 3\u00a0mg\/g gel improves patient-reported outcomes in severe facial erythema of rosacea. In: EADV. 2014; P1853."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-015-0078-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T14:30:32Z","timestamp":1498228232000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13555-015-0078-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,26]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["78"],"URL":"https:\/\/doi.org\/10.1007\/s13555-015-0078-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,26]]}}}